Haemonetics (HAE)
(Delayed Data from NYSE)
$95.27 USD
-0.46 (-0.48%)
Updated May 20, 2024 04:00 PM ET
After-Market: $95.31 +0.04 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$95.27 USD
-0.46 (-0.48%)
Updated May 20, 2024 04:00 PM ET
After-Market: $95.31 +0.04 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth B Momentum B VGM
Zacks News
Why Is Haemonetics (HAE) Up 9.2% Since Last Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics Strong on Plasma Unit Amid Blood Center Weakness
by Zacks Equity Research
Haemonetics (HAE) witnesses strong growth in Plasma franchise. Dullness in Blood Center business prevails.
Cardiovascular Systems Posts 2-Year LIBERTY 360 Study Data
by Zacks Equity Research
The 24-month outcome of LIBERTY 360 study by Cardiovascular Systems (CSII) demonstrates a constant relief from major amputation across all Rutherford Classifications (RC).
Haemonetics (HAE) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Haemonetics' (HAE) year-over-year growth is backed by the solid execution of its multi-year turnaround strategy.
Zacks.com highlights: Lululemon Athletica, Sirius XM Holdings, Haemonetics, Lockheed Martin and ConocoPhillips
by Zacks Equity Research
Zacks.com highlights: Lululemon Athletica, Sirius XM Holdings, Haemonetics, Lockheed Martin and ConocoPhillips
Buy These 5 Efficient Stocks for Superb Returns
by Tirthankar Chakraborty
A company with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with the stock's price performance.
Haemonetics Gains on Strong Plasma, Wider Global Footprint
by Zacks Equity Research
Strong growth of Haemonetics' (HAE) plasma-derived biopharmaceuticals is attributable to solid end-market demand.
Haemonetics' Plasma Momentum Solid, Margins Gain Traction
by Zacks Equity Research
Solid end-market demand for plasma-derived biopharmaceuticals continues to drive growth for Haemonetics (HAE).
Why is Haemonetics (HAE) Up 15.6% Since Its Last Earnings Report?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) Q4 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Continued generation of new business and geographical expansion drive Haemonetics' (HAE) Q4 results.
Medical Product Stocks May 8 Earnings List: HSIC, PEN & More
by Urmimala Biswas
An important component of the broader Medical sector, the Medical Product space consistently grabs attention owing to a string of upsides.
Haemonetics Rides High on Plasma, Blood Center Remains Weak
by Zacks Equity Research
We are optimistic about Haemonetics' (HAE) improved Plasma franchise as strong end-market demand for plasma-derived biopharmaceuticals consistently drives growth for the company.
SRDX or HAE: Which is a Better Medical Product Stock?
by Zacks Equity Research
Here we analyze the financials and fundamental factors of Haemonetics (HAE) and Surmodics (SRDX) to decide which is a better investment option.
Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance
by Zacks Equity Research
Haemonetics (HAE) witnesses steady growth in Plasma franchise, led by strong end-market demand for plasma-derived biopharmaceuticals.
Zacks.com highlights: Haemonetics, Alarm.com Holdings, Copart and inTEST
by Zacks Equity Research
Zacks.com highlights: Haemonetics, Alarm.com Holdings, Copart and inTEST
Buy These 4 Efficient Stocks for Impressive Returns
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
Why Should You Add Haemonetics (HAE) to Your Portfolio Now?
by Zacks Equity Research
Market seems to be upbeat about Haemonetics' (HAE) newly-launched platform, NexSys Plasma Collection System (PCS).
Cerus (CERS) Looks Good: Stock Adds 9.5% in Session
by Zacks Equity Research
Shares of Cerus (CERS) rose 9.5% on Friday
Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips
by Zacks Equity Research
Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips
5 Top-Ranked Efficient Stocks to Boost Your Portfolio
by Tirthankar Chakraborty
A company with a favorable efficiency level will provide impressive returns irrespective of market conditions
Haemonetics (HAE) Up 4.2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Haemonetics (HAE) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Haemonetics (HAE) upbeat on integration of NexSys PCS device. A raised EPS guidance buoys optimism.
Medical Device Industry Outlook - February 2018
by Zacks Equity Research
Amid the concerns related to the tax reform, Congress' postponement of the medical device tax for another two years came as a huge relief to industry participants and investors.
Here's Why You Must Add Haemonetics (HAE) to Your Portfolio
by Zacks Equity Research
Haemonetics (HAE) delivers strong plasma revenues, driven by a robust performance in disposables and software in the United States. Also, the market seems upbeat about this new PCS platform.
Zacks.com featured highlights include: Lululemon, Haemonetics, NVR, YY and ConocoPhillips
by Zacks Equity Research
Zacks.com featured highlights include: Lululemon, Haemonetics, NVR, YY and ConocoPhillips